

**HEMMOREX-HC- hydrocortisone acetate suppository**  
**Laser Pharmaceuticals, LLC**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.*

-----  
**Hemmorex-HC**

**HEMMOREX-HC™**


(hydrocortisone acetate suppositories), 25mg

Rx Only

For Rectal Administration

**DESCRIPTION:**

Hydrocortisone acetate is a corticosteroid designed chemically as pregn-4-ene 3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy—(11 β) with the following structural formula:



Each rectal suppository contains hydrocortisone acetate, USP 25 mg in a specially blended hydrogenated vegetable oil base.

**CLINICAL PHARMACOLOGY:**

In normal subjects, about 26% of hydrocortisone acetate is absorbed when the suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.

**INDICATIONS AND USAGE:**

Hemmorex-HC™ suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani.

**CONTRAINDICATIONS:**

Hemmorex-HC™ suppositories are contraindicated in those patients having a history of hypersensitivity to hydrocortisone acetate or any of the components.

**PRECAUTIONS:**

Do not use Hemmorex-HC™ suppositories unless adequate proctologic examination is made. If irritation develops, the product should be discontinued and appropriate therapy instituted. In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Hemmorex-HC™ should be discontinued until the infection has been adequately controlled.

**Carcinogenesis:**

No long term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

**Pregnancy Category C:**

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well controlled studies in pregnant women. Hemmorex-HC™ suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

It is not known whether this drug is excreted in human milk and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Hemmorex-HC™ suppositories, a decision should be

made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**ADVERSE REACTIONS:**

The following local adverse reactions have been reported with corticosteroid suppositories; burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, secondary infection.

**DRUG ABUSE AND DEPENDENCE:**

Drug abuse and dependence have not been reported in patients treated with Hemmorex-HC™ suppositories.

**OVERDOSAGE:**

If signs and symptoms of systemic overdose occur, discontinue use.

**DOSAGE AND ADMINISTRATION:**

For rectal administration. Detach one suppository from strip of suppositories. Remove the wrapper. Avoid excessive handling of the suppository which is designed to melt at body temperature. Insert suppository into the rectum with gentle pressure, pointed end first. Insert one suppository in the rectum twice daily, morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times a day or two suppositories twice daily. In factitial proctitis, the recommended duration of therapy is six to eight weeks or less, according to the response of the individual case.

All prescription substitutions and/or recommendations using this product shall be made subject to state

and federal statutes as applicable. **Please NOTE: This is not an Orange Book product and has not been subjected to FDA therapeutic or other equivalency testing. No representation is made as to generic status or bioequivalency.** Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information provided herein.

**HOW SUPPLIED:**

Hemmorex-HC™ (hydrocortisone acetate suppositories), 25mg are off-white, smooth surfaced and bullet shaped with one pointed end.

Box of 12 and 24 suppositories, NDC 16477-201-12 and NDC 16477-201-24.

**STORAGE:**

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Excursions permitted to 15°-30°C (59°-86°F). Store away from heat. Protect from freezing.

Manufactured for:

Laser Pharmaceuticals, LLC  
1015 Nine North Drive, Ste 400  
Alpharetta, GA 30004

770-754-9846

Rev. 04/20



## HEMMOREX-HC

hydrocortisone acetate suppository

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:16477-201
<b>Route of Administration</b>	RECTAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HYDROCORTISONE ACETATE (UNII: 3X7931PO74) (HYDROCORTISONE - UNII:WI4X0X7BPJ)	HYDROCORTISONE ACETATE	25 mg

## Inactive Ingredients

Ingredient Name	Strength
HYDROGENATED PALM KERNEL OIL (UNII: FM8D1RE2VP)	

## Product Characteristics

Color	yellow (off-white)	Score	
Shape	BULLET	Size	
Flavor		Imprint Code	
Contains			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:16477-201-12	12 in 1 BOX; Type 0: Not a Combination Product	11/12/2013	
2	NDC:16477-201-24	24 in 1 BOX; Type 0: Not a Combination Product	11/12/2013	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		11/12/2013	

**Labeler** - Laser Pharmaceuticals, LLC (614417132)

Revised: 5/2020

Laser Pharmaceuticals, LLC